Trial reportStroke2003
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
Trial report in Stroke, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02765399 (The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study
Open the trial in the graphWho cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.The Cochrane database of systematic reviews · 2023Pooled it
- Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.The Cochrane database of systematic reviews · 2017Pooled it
- Acute Effects of Kawakawa (Nutrients · 2022Trial
- Mifepristone Improves Adipose Tissue Insulin Sensitivity in Insulin Resistant Individuals.The Journal of clinical endocrinology and metabolism · 2021Trial
- Appetite-Regulating Hormones Are Reduced After Oral Sucrose vs Glucose: Influence of Obesity, Insulin Resistance, and Sex.The Journal of clinical endocrinology and metabolism · 2021Trial
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.The New England journal of medicine · 2016 · on this mapTrial
- Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.American heart journal · 2014Trial
- Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut origin.PloS one · 2014Trial
- Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals.Arthritis research & therapy · 2012Trial
- Melatonin and mitochondrial protection in cardiac ischemia-reperfusion injury: mechanisms, evidence and translational perspectives.Basic research in cardiology · 2026Review
- Capturing metabolic syndrome: new thresholds for insulin resistance and novel body composition indices.International journal of obesity (2005) · 2026Article
- Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.Journal of cellular and molecular medicine · 2026Review
- Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.The Journal of clinical endocrinology and metabolism · 2025 · on this mapReview
- Improved detection of decreased glucose handling capacities via continuous glucose monitoring-derived indices.Communications medicine · 2025Article
- Aging delays the suppression of lipolysis and fatty acid oxidation in the postprandial period.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Article
- Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysisFrontiers in public health · 2023Review
- The evolution of glucose-insulin homeostasis in children with β-thalassemia major (β -TM): A twenty-year retrospective ICET- A observational analysis from early childhood to young adulthood.Acta bio-medica : Atenei Parmensis · 2022Observational
- Evolution of Combined Impaired Fasting Glucose and Impaired Glucose Tolerance in β-Thalassemia Major: Results in 58 Patients with a Mean 7.7- year Follow-Up.Acta bio-medica : Atenei Parmensis · 2022Article
- Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review).International journal of molecular medicine · 2021Review
- Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients.Scientific reports · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
background and purposeThe aim of this study was to determine the effectiveness of pioglitazone compared with placebo for improving insulin sensitivity among nondiabetic patients with a recent transient ischemic attack (TIA) or nondisabling ischemic stroke and impaired insulin sensitivity.
methodsEligible subjects were men and women >45 years of age who had no history of diabetes, fasting glucose <7.0 mmol/L, and impaired insulin sensitivity according to an index calculated from insulin and glucose blood levels obtained during an oral glucose tolerance test. Eligible subjects were randomized to pioglitazone 45 mg/d or placebo. After 3 months of therapy, the glucose tolerance test was repeated.
resultsBetween July 2000 and June 2001, we performed oral glucose tolerance tests on 75 patients with no history of diabetes, among whom 36 (50%) were found to have impaired insulin sensitivity and fasting glucose <7.0 mmol/L. Among these 36, 20 consented to the trial. Patients assigned to pioglitazone (n=10) and placebo (n=10) were similar in insulin sensitivity, age, obesity, and index event (stroke compared with TIA), but patients assigned to pioglitazone were less likely to be male (4 compared with 9). The mean proportional increase in insulin sensitivity was 62% among patients assigned to pioglitazone compared with a -1% decline among patients assigned to placebo (P=0.0006). Mean C-reactive protein concentration declined from 0.30 to 0.20 mg/L among patients assigned to pioglitazone and increased from 0.41 to 0.45 mg/L among patients assigned to placebo (P=0.06 for comparison of mean change).
conclusionsPioglitazone is effective for improving insulin sensitivity among patients with recent TIA or stroke and impaired insulin sensitivity.
Indexed as
Identifiers
12730556What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.